Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. Academic Article uri icon

Overview

abstract

  • Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials using both the intravenous and the oral forms. In this review, we present a systematic overview of these trials.

publication date

  • January 1, 2001

Identity

PubMed Central ID

  • PMC59641

Digital Object Identifier (DOI)

  • 10.1067/mhj.2000.105107

PubMed ID

  • 11806792

Additional Document Info

volume

  • 2

issue

  • 4